Harnessing approaches to information
unavailable until now, systems biology focuses on studying the complex interactions among
vast numbers
of biological elements working as a whole rather than by examining single genes, proteins,
or pathogens. “Since the completion of the human genome sequence,” says Perlmutter, “we
now know the 30,000 or so human genes that encode every single one of the proteins that
make us up.”
Living on the leading edge of a revolution in biology and medicine is far from a new
experience for Perlmutter. As Amgen’s executive vice president for research and development
since 2001, he directs a group of scientists who work on the cutting edge of discovery
at the world’s largest and most successful biotechnology company.
It took him more than two decades after entering Reed as an English literature major
in the late ’60s to work through the fields of chemistry, biology, and finally immunology
before coming back to drug development, first at pharmaceutical giant Merck and more recently
at Amgen. Perlmutter says it was a restless imagination and something in Reed College’s
environment that led him in a series of different directions. “In
an interesting sort of way, my thesis work at Reed College was actually related to drug
discovery and the adverse effects of drugs, though I didn’t get back to that kind
of thing for 20 years,” he says. “I was, at the time, interested in drugs that could
be immunosuppressants, and I went on to study immunology and molecular biology and worked
in drug discovery. |
 |
| Perlmutter predicts that doctors in the coming decades will
be practicing a far more personalized form of medicine. Using genetic patterns to predict
illnesses before they
present themselves, future physicians will be tailoring therapies to fit the person |
|